193 related articles for article (PubMed ID: 12668132)
1. Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer.
Furuhata S; Ide H; Miura Y; Yoshida T; Aoki K
Mol Ther; 2003 Mar; 7(3):366-74. PubMed ID: 12668132
[TBL] [Abstract][Full Text] [Related]
2. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells.
Andriani F; Nan B; Yu J; Li X; Weigel NL; McPhaul MJ; Kasper S; Kagawa S; Fang B; Matusik RJ; Denner L; Marcelli M
J Natl Cancer Inst; 2001 Sep; 93(17):1314-24. PubMed ID: 11535706
[TBL] [Abstract][Full Text] [Related]
3. Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth.
Sung SY; Chang JL; Chen KC; Yeh SD; Liu YR; Su YH; Hsueh CY; Chung LW; Hsieh CL
PLoS One; 2016; 11(4):e0153350. PubMed ID: 27054343
[TBL] [Abstract][Full Text] [Related]
4. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
[TBL] [Abstract][Full Text] [Related]
6. Differential transactivation by the androgen receptor in prostate cancer cells.
Snoek R; Bruchovsky N; Kasper S; Matusik RJ; Gleave M; Sato N; Mawji NR; Rennie PS
Prostate; 1998 Sep; 36(4):256-63. PubMed ID: 9719026
[TBL] [Abstract][Full Text] [Related]
7. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer.
Hall SJ; Mutchnik SE; Yang G; Timme TL; Nasu Y; Bangma CH; Woo SL; Shaker M; Thompson TC
Cancer Gene Ther; 1999; 6(1):54-63. PubMed ID: 10078964
[TBL] [Abstract][Full Text] [Related]
8. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
9. A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer.
Cheng WS; Kraaij R; Nilsson B; van der Weel L; de Ridder CM; Tötterman TH; Essand M
Mol Ther; 2004 Aug; 10(2):355-64. PubMed ID: 15294182
[TBL] [Abstract][Full Text] [Related]
10. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo.
Zhang J; Thomas TZ; Kasper S; Matusik RJ
Endocrinology; 2000 Dec; 141(12):4698-710. PubMed ID: 11108285
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models.
Eastham JA; Chen SH; Sehgal I; Yang G; Timme TL; Hall SJ; Woo SL; Thompson TC
Hum Gene Ther; 1996 Mar; 7(4):515-23. PubMed ID: 8800746
[TBL] [Abstract][Full Text] [Related]
12. Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues.
Takakuwa K; Fujita K; Kikuchi A; Sugaya S; Yahata T; Aida H; Kurabayashi T; Hasegawa I; Tanaka K
Jpn J Cancer Res; 1997 Feb; 88(2):166-75. PubMed ID: 9119745
[TBL] [Abstract][Full Text] [Related]
13. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer.
Coulter JA; Page NL; Worthington J; Robson T; Hirst DG; McCarthy HO
J Gene Med; 2010 Sep; 12(9):755-65. PubMed ID: 20821746
[TBL] [Abstract][Full Text] [Related]
15. Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB.
Zhang Y; Yu J; Unni E; Shao TC; Nan B; Snabboon T; Kasper S; Andriani F; Denner L; Marcelli M
Hum Gene Ther; 2002 Nov; 13(17):2051-64. PubMed ID: 12490000
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
17. Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer.
Ikegami S; Tadakuma T; Ono T; Suzuki S; Yoshimura I; Asano T; Hayakawa M
Cancer Sci; 2004 Apr; 95(4):367-70. PubMed ID: 15072597
[TBL] [Abstract][Full Text] [Related]
18. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antitumor activity by probasin promoter-directed p202 expression.
Wen Y; Giri D; Yan DH; Spohn B; Zinner RG; Xia W; Thompson TC; Matusik RJ; Hung MC
Mol Carcinog; 2003 Jul; 37(3):130-7. PubMed ID: 12884364
[TBL] [Abstract][Full Text] [Related]
20. Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.
Xie X; Kong Y; Tang H; Yang L; Hsu JL; Hung MC
Mol Cancer Ther; 2014 Jul; 13(7):1813-25. PubMed ID: 24785255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
